US 11414489
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
granted A61KA61K2039/54A61K2039/545
Quick answer
US patent 11414489 (Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor) held by HALOZYME, INC. expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- HALOZYME, INC.
- Grant date
- Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K2039/54, A61K2039/545, A61K31/573, A61K38/47